Enliven Therapeutics (ELVN) Income from Continuing Operations (2019 - 2026)

Enliven Therapeutics has disclosed Income from Continuing Operations across 8 years of filings, most recently posting 23627000.0 for Q1 2026.

• Income from Continuing Operations for Q1 2026 came in at 23627000.0, up 17.09% year-over-year; the trailing twelve-month figure through Mar 2026 was 891000.0 (up 99.07% YoY), and the FY2025 annual result was 5761000.0, up 93.59% from the prior year.
• Income from Continuing Operations came in at 23627000.0 for Q1 2026 at Enliven Therapeutics, down from 68217000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 68217000.0 in Q4 2025 to a low of 28497000.0 in Q1 2025.
• The 5-year median for Income from Continuing Operations is 20148000.0 (2025), against an average of 13441588.24.
• Across the five-year window, Income from Continuing Operations sank 102.73% in 2023 and jumped 394.29% in 2025, its largest moves.
• Enliven Therapeutics' Income from Continuing Operations stood at 9550000.0 in 2022, then tumbled by 102.73% to 19361000.0 in 2023, then decreased by 19.73% to 23180000.0 in 2024, then surged by 394.29% to 68217000.0 in 2025, then slumped by 134.64% to 23627000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 23627000.0 (Q1 2026), 68217000.0 (Q4 2025), and 20148000.0 (Q3 2025), per Business Quant data.